LTRN

Lantern Pharma Inc

0.6023

Nov 03 • 3:59 PM ET -0.0377 (-5.89%)

0.5700

Aftermarket • 5:14 PM ET -0.0323 (-5.36%)

Healthcare Biotechnology USA Nano NASD

Peers: RXRX HYFT ABSI LNAI TPST ACTU CRDF KZIA OSTX SDGR

| Held by: VTI VXF MEDX DFSU DFAC

Scroll to Statements

Index	-
Market Cap	9.00M
Enterprise Value	1.68M
Income	-18.65M
Sales	0.00M
Book/sh	-0.25
Cash/sh	0.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Jun 11, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	1.22
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.96
Current Ratio	1.96
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.61
EPS next Y	-2.02
EPS next Q	-0.35
EPS this Y	-3.82%
EPS next Y	-23.93%
EPS next 5Y	-10.36%
EPS past 3/5Y	-6.13% -10.59%
Sales past 3/5Y	- -
EPS Y/Y TTM	9.68%
Sales Y/Y TTM	-
EPS Q/Q	-41.76%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-50.00% -

Insider Own	22.23%
Insider Trans	3.01%
Inst Own	25.75%
Inst Trans	-1.16%
ROA	-143.36%
ROE	-400.92%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.58%
SMA50	-51.10%
SMA200	-75.26%
Trades

Shs Outstand	12.76M
Shs Float	11.61M
Short Float	3.35%
Short Ratio	1.67
Short Interest	0.39M
52W High	4.34 -86.12%
52W Low	0.59 1.91%
Volatility	16.75% 13.60%
ATR (14)	0.11
RSI (14)	28.67
Beta	2.46
Rel Volume	0.80
Avg Volume	232.83K
Volume	185,464

Perf Week	-5.89%
Perf Month	-35.93%
Perf Quarter	-78.49%
Perf Half Y	-72.12%
Perf YTD	-80.12%
Perf Year	-84.23%
Perf 3Y	-79.01%
Perf 5Y	-94.22%
Perf 10Y	-
Recom	1.00
Target Price	18.00
Prev Close	0.64
Price	0.60
Change %	-5.89%

Consensus

Strong Buy

Avg. Price Target

$18.00

Implied Upside

+2,888.5%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 07, 2021	Initiated	HH.C. Wainwright	Buy	$32	+5,213.0%

Oct-08-26 07:58PM	What Could Go Wrong With Recursion Pharmaceuticals Stock? (Trefis) -8.79%
08:00AM	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 (Business Wire)
07:05AM	Lantern Pharma secures Taiwan clearances for Phase II NSCLC study (Clinical Trials Arena)
Oct-07-26 08:31AM	Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC (Business Wire)
Sep-30-26 04:01PM	Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering (Business Wire) -6.91%
08:00AM	Loading…
Sep-29-26 08:00AM	Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering (Business Wire)
Sep-23-26 07:45AM	Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET (Business Wire)
Sep-22-26 07:45AM	Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas (Business Wire) -9.33%
Sep-17-26 08:20AM	Lantern Pharma to Present Open-Medicine AI - a Multi-Agentic Platform for End-to-End Therapeutic Development - Business Model, Roadmap, and Value Proposition on September 23 (Business Wire) -11.40%
Aug-19-26 09:03PM	Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ... (GuruFocus.com) -8.03%
Aug-14-26 07:30AM	Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Aug-07-26 08:00AM	Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET (Business Wire)
Aug-03-26 07:30AM	Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine (Business Wire)
Jul-28-26 07:45AM	Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer (Business Wire) -6.81%
Jul-23-26 08:01AM	Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers (Business Wire)
07:30AM	Loading…
Jul-08-26 07:30AM	Lantern Pharma Launches ZetaOmics - an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer (Business Wire) -13.17%
May-19-26 07:30AM	Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC Phase 2 Trial of LP-300 in Never-Smokers with NSCLC (Business Wire)
May-15-26 04:01PM	Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
May-14-26 04:05PM	Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor (Business Wire) +24.70%
May-13-26 08:00AM	Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor (Business Wire) +21.84%
May-11-26 04:30PM	Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 (Business Wire)
May-07-26 09:01AM	Lantern Pharma Unveils Roadmap for withZeta.ai - Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm and ZetaOmics (Business Wire)
Apr-29-26 08:50AM	Lantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence - Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally (Business Wire) -11.61%
Apr-24-26 07:50AM	Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut (Business Wire) +6.49%
Apr-14-26 08:31AM	Lantern Pharma Launches withZeta.ai the Worlds First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22 (Business Wire)
Apr-02-26 09:00PM	Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) +14.08%
08:10AM	Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai the World's First Multi-Agentic Co-Scientist for Rare Cancers 8:30 AM Eastern, April 9, 2026 (Business Wire)
Mar-30-26 04:05PM	Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (Business Wire) +10.27% +10.93%
Mar-27-26 07:29AM	Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 (Business Wire) -46.41%
Mar-23-26 04:30PM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET (Business Wire) +5.16%
11:19AM	Loading…
Feb-12-26 11:19AM	Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition (Insider Monkey) -5.61%
Feb-10-26 08:45AM	Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 (Business Wire) +7.38%
Jan-20-26 08:00AM	Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas (Business Wire)
Jan-12-26 09:00AM	Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR Platform and Accelerate Global Development Opportunities with BioPharma Companies (Business Wire)
Dec-03-25 08:35AM	Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials (Business Wire)
Nov-13-25 08:30AM	Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Nov-06-25 08:00AM	Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET (Business Wire) -5.35%
Oct-30-25 08:00AM	Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT (Business Wire)
Oct-28-25 08:49AM	Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. (Business Wire)
Oct-24-25 08:00AM	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 (Business Wire) +10.27%
Sep-16-25 08:29AM	Lantern Pharmas LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors (Business Wire) +7.61%
Sep-03-25 09:44AM	Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial (Business Wire) +6.45%
Aug-13-25 04:30PM	Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates (Business Wire) +6.97%
Aug-07-25 05:34AM	FDA clears Starlight Therapeutics IND for Phase Ib/IIa glioblastoma trial (Clinical Trials Arena)
Aug-06-25 08:30AM	Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial (Business Wire)
Aug-04-25 08:55AM	Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai (Business Wire) +11.53%
Aug-01-25 05:45AM	Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan (Clinical Trials Arena) +7.43%
Jul-31-25 07:30AM	Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic Clinical Trial in Japan for LP-300 (Business Wire) +10.72%
Jul-28-25 08:00AM	Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors (Business Wire) -5.31%
Jul-23-25 07:56AM	Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial (Business Wire)
Jul-21-25 08:20AM	Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy (Business Wire) -5.01%
Jul-16-25 08:30AM	IBN Initiates Coverage of Lantern Pharma Inc. (GlobeNewswire) +6.12%
Jul-15-25 09:40AM	Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment (Business Wire) -5.76%
Jun-16-25 08:30AM	Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years (Business Wire)
May-29-25 11:21PM	Lantern Pharma Inc. (LTRN)'s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models (Insider Monkey) +9.06%
08:30AM	Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials (Business Wire)
May-15-25 08:45AM	Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates (Business Wire)
May-12-25 09:00AM	Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need (Business Wire)
08:31AM	EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients (Benzinga)
May-08-25 08:30AM	Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET (Business Wire) -11.06%
May-05-25 08:55AM	Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) (Business Wire)
08:31AM	EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial (Benzinga)
Apr-01-25 09:01PM	Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com) -6.50%
Mar-27-25 08:35PM	Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:01PM	Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results (Business Wire)
Mar-20-25 08:00AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET (Business Wire)
Mar-12-25 06:00AM	How long-term energy plays outshine short-term hype (Yahoo Finance Video) +7.56%
Feb-20-25 04:14PM	Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech (Insider Monkey) -6.68%
Feb-19-25 08:00AM	Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates (Business Wire)
Jan-27-25 06:54PM	Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies (Insider Monkey) -15.00%
07:55AM	Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer (Business Wire)
Jan-17-25 01:29PM	Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development (Insider Monkey)
Dec-10-24 10:40AM	AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan (Insider Monkey)
Dec-09-24 12:21PM	Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial (Clinical Trials Arena)
08:15AM	Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Dec-07-24 01:59AM	Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer (Insider Monkey)
Dec-03-24 08:00AM	Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) (Business Wire)
Nov-26-24 08:45AM	Lantern Pharma and Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality (Business Wire)
Nov-19-24 08:00AM	Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Nov-08-24 06:03PM	Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +12.28% -8.59%
Nov-07-24 04:05PM	Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Nov-05-24 08:00AM	Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board (Business Wire)
Oct-31-24 08:00AM	Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET (Business Wire)
Oct-23-24 08:45AM	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 (Business Wire)
Oct-21-24 08:00AM	Lantern Pharma to Host & Participate in Two Public Webinars During October (Business Wire)
Oct-15-24 09:07AM	Lantern Pharmas Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA (Business Wire)
Oct-09-24 05:56PM	Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
Sep-23-24 08:00AM	Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Childrens Cancers (Business Wire)
Aug-31-24 02:02PM	Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-08-24 04:01PM	Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates (Business Wire) -7.68%
Aug-07-24 09:31AM	Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 (Business Wire) +12.26%
Aug-05-24 08:00AM	Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort (Business Wire) -5.88%
Aug-01-24 08:00AM	Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET (Business Wire)
Jul-10-24 08:30AM	Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 (Business Wire)
Jun-12-24 07:30AM	Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 (Business Wire)
May-23-24 11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-09-24 04:02PM	Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.09% -9.54%
May-06-24 06:41AM	Lantern Pharma and Oregon partner to develop cancer treatment (Pharmaceutical Technology) +11.38%
04:37AM	Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration (MT Newswires)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schalop Lee Troy	Director	May 12 '26	Buy	2.06	48,544	100,001	48,544	May 14 04:10 PM
KEYSER D JEFFREY	Director	May 12 '26	Buy	2.06	48,544	100,001	94,303	May 14 04:10 PM

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

PresidentMr. Panna Sharma

CFO & SecretaryMr. David R. Margrave

Chief Scientific Officer & Scientific ConsultantDr. Kishor Gopaldas Bhatia Ph.D.

M.S.Dr. Peter L. Nara D.V.M.

Chief Medical Officer of Starlight TherapeuticsDr. Marc C. Chamberlain M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LTRN

Lantern Pharma Inc

Upgrade your Finviz experience